You have 9 free searches left this month | for more free features.

Non-Hodgkin's lymphomas

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma
  • +4 more
  • (no location specified)
Dec 7, 2022

Non Hodgkin Lymphoma Trial in Cleveland (UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin Lymphoma
  • UF-KURE19 CAR-T cells
  • +2 more
  • Cleveland, Ohio
  • +1 more
Nov 21, 2022

Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)

Recruiting
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Jan 25, 2023

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)

Recruiting
  • Epstein-Barr Virus Infections
  • +3 more
  • Nivolumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))

Active, not recruiting
  • Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
  • Blinatumomab Expanded T-cells (BET)
  • Bergamo, Italy
    ASST - Papa Giovanni XXIII
Dec 22, 2021

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United

Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +7 more
Apr 28, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • +13 more
  • (no location specified)
Aug 29, 2023

Hodgkins Lymphoma, Non Hodgkins Lymphoma Trial in Houston (TAA-specific CTLs)

Recruiting
  • Hodgkins Lymphoma
  • Non Hodgkins Lymphoma
  • TAA-specific CTLs
  • Houston, Texas
    Texas Children's Hospital
Jul 14, 2022

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022

Lymphoma Trial in New York (pralatrexate)

Completed
  • Lymphoma
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Aug 20, 2021

T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

Recruiting
  • T-cell Non-Hodgkin Lymphoma
  • Lymphoma, Extranodal NK-T-Cell
  • Busan, Korea, Republic of
  • +1 more
Aug 17, 2022

Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • +5 more
  • (no location specified)
Dec 2, 2022

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Morgantown (Busulfan, Fludarabine)

Active, not recruiting
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Morgantown, West Virginia
    West Virginia University Hospitals Mary Babb Randolph Cancer Cen
Apr 6, 2021